


## AMENDMENTS TO THE CLAIMS

1) (Currently amended) Amino acid diamides in non- $\alpha$  position of formula (1)



(1)


wherein:

$n = 2$  to  $8$ ;

$R_1$  is selected from ~~amongst~~ the group consisting of ~~functional groups~~ alkyl halogen,  $\text{NO}_2$ ,  $\text{OH}$ ,  $\text{OCH}_3$  ~~either alone or associated and a combination thereof~~; and

$R_2$  is selected from the group consisting of ~~functional groups~~ H, alkyl, halogen,  $\text{NO}_2$ ,  $\text{OH}$ , and  $\text{OCH}_3$ , ~~which are useful as adjuvants for the administration of biological active agents.~~


2) (Currently amended) ~~Compounds~~ Diamides according to claim 1, ~~wherein they present the following structure comprising:~~



(2)

wherein  $n = 2$  to  $8$ .


3) (Currently amended) ~~Compounds~~ Diamides according to claim 1, ~~wherein they present the following structure comprising:~~



(3)

wherein  $n = 2$  to 8.

4) (Currently amended) Compounds according to claim 1, wherein they present the following structure:



$n = 2$  to 8

(4).

5) (Currently amended) ~~Pharmaceutical compositions according to claim 1, wherein they comprise heparin oligosaccharides and at least one compound from formula (1)~~ A pharmaceutical composition comprising heparin oligosaccharides and at least one compound according to claim 1.


6) (Currently amended) ~~Pharmaceutical compositions according to claim 5, wherein they comprise compounds according to formula (2) and glycosaminoglycan oligosaccharides~~ A pharmaceutical composition comprising at least one compound according to claim 2 and glycosaminoglycan oligosaccharides.

7) (Currently amended) ~~Pharmaceutical compositions according to claim 5, wherein they comprise compounds according to formula (3) and glycosaminoglycan oligosaccharides~~ A

pharmaceutical composition comprising at least one compound according to claim 3 and glycosaminoglycan oligosaccharides.


8) (Currently amended) ~~Pharmaceutical compositions according to claim 5, wherein they comprise compounds according to formula (4) and glycosaminoglycan oligosaccharides~~ A pharmaceutical composition comprising at least one compound according to claim 4 and glycosaminoglycan oligosaccharides.

9) (Currently amended) A pharmaceutical composition ~~Pharmaceutical compositions~~ according to claim 5, ~~wherein they comprise at least one compound of structure comprising~~




and Bemiparin.

10) (Currently amended) A pharmaceutical composition ~~Pharmaceutical compositions~~ according to claim 5, ~~wherein they comprise at least one compound of structure comprising~~



and Bemiparin.

11) (Currently amended) ~~A pharmaceutical composition~~ Pharmaceutical compositions according to claim 5, ~~wherein they comprise at least one compound of structure comprising~~



and Bemiparin.

12) (Currently amended) ~~A pharmaceutical composition~~ Pharmaceutical compositions according to claim 1, ~~wherein they comprise compounds at least one compound~~ according to formula (1) and at least one active agent selected from the group ~~composed~~ consisting of heparin, dermatan sulphate, chondroitin sulphate, heparan sulphate and oligosaccharide derivatives.

13) Canceled.

14) Canceled.

15) (New) A method of enhancing the colonic absorption of a glycosaminoglycan or glycosaminoglycan oligosaccharide following administration thereof, the method comprising: orally or intracolonicly administering to a subject in need thereof a compound according to any one of claims 1 – 4 or 5 and a glycosaminoglycan or glycosaminoglycan oligosaccharide thereby enhancing the colonic absorption of the glycosaminoglycan or glycosaminoglycan oligosaccharide.

16) (New) A method of treating thrombosis, inflammation, cancer or allergy comprising: administering to a subject in need thereof a compound according to any one of claims 1 – 4 or 5 and a glycosaminoglycan or glycosaminoglycan oligosaccharide.

17) (New) The method of claim 16, wherein the step of administering is selected from the group consisting of oral, intraduodenal, intracolonic and pulmonary administration.